|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.44/-1.24
|
企业价值
905.13M
|
资产负债 |
每股账面净值
3.73
|
现金流量 |
现金流量率
--
|
损益表 |
收益
177.13M
|
每股收益
4.31
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/14 01:28 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy. The company generates all of its revenue in the United States. |